about
Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepinesCombretastatins: more than just vascular targeting agents?Aromatic bis-N-hydroxyguanidinium derivatives: synthesis, biophysical, and biochemical evaluations.Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.Lead identification of β-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.Peripheral-type benzodiazepine receptors.PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cellsAntitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cellsβ-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.Development of novel cyclic peptides as pro-apoptotic agents.Isouronium and N-hydroxyguanidinium derivatives as Cell growth inhibitors: A comparative study.The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells.Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines.Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway.Guanidinium-based derivatives: searching for new kinase inhibitors.The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells.Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells.Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe.Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies.Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro.Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines.The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin.Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells.BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines.Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives.STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.Pyrrolo[1,5]benzoxa(thia)zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target.
P50
Q28078909-413DD798-D362-4D4F-B21E-A94BE4A9CAF1Q28080764-D9FB23C2-AD40-4A57-A063-F1BF2D701959Q30582292-FD9D5FD6-4D89-440B-A45D-F3BB4C19A5C6Q31725751-3683C3E7-FF5F-41CD-9FBB-04AB41881925Q33847866-3E2B9131-0822-4DBB-9E31-30AC99E62E06Q34150086-6D10CFDC-F153-4B81-BE2C-9C14415A5E4EQ34216670-DA228992-E5AB-4E70-825B-D53C1BA38961Q34447232-FBF31C26-C5BE-4E89-A8A5-32FCB78FEEB2Q34543759-3CE6A650-6453-4EF6-A511-68A91188E05EQ37216913-62A66727-7E26-4958-B0F6-8ED2E5248620Q38714088-1C23AEAC-F3E2-48F9-A685-F75E0507CB4AQ38758459-8EDB9022-1322-4217-B8FE-B80CCA6C6D54Q38773013-9F1D697D-911D-49F9-A181-E0DB290C9EE1Q38775960-4A703804-D224-4438-AC4D-1817FC0775EAQ38793522-AF9CBBBF-B42A-4544-8D09-81A5EB0D8016Q38810858-52304D4A-DA71-4FF7-9106-D761709074A5Q38849601-00DE98E3-9C1B-40F1-B825-8ACF70D1F484Q38871363-486160D9-0233-438F-AE0F-75D922E741A5Q38934739-DC956C27-0B67-4F8E-81B7-B908C73AD3B2Q38991956-03226B36-695C-41B6-AB28-F98F828A8197Q39035963-4B750653-386C-4753-BCD7-43BA9F1E2EE7Q39135307-0DD56CBE-B0FB-4E33-9A7B-434EB618D0C7Q39227629-EE96D9D0-FBF7-4476-92FD-3A799A781875Q39490537-CAFE13F3-B97F-4612-AFD2-ACC9CB8A1436Q39577197-AA6189F8-1753-46AB-AAE4-8AE41A11AA69Q39592595-B5511B00-42A8-48FC-B20E-A713B93F1FAEQ39623782-14EAB95E-93D2-41B7-A0D9-C0B0489C28C9Q39646476-0B6C1DB9-5C64-456A-9B2C-C0B6DF0B25E3Q39668887-41246A3D-0522-4694-9534-AF107160E8FBQ39728931-350FAFD0-8D0F-4003-BA4D-0ACE0EB433A5Q39845575-D1FE3E7C-07F5-4ECA-9498-ED1382874030Q39915631-4D975556-684A-4463-9E0C-B25FD6539F81Q39932658-3B4E5355-9304-4BDE-BAFE-A814C89B60CCQ40013839-2322691A-C762-41A8-969B-30E4774955B0Q40045511-426DD4B9-7772-4D4E-9800-1A4AC40ADA94Q40054333-0151FAE4-7587-427E-AA1B-16DC743C7170Q40161324-12D9F170-A6A0-42EE-A7A2-FB8B4E48E735Q40187289-014A22A2-8D11-4A5F-A9DF-203F9E74BD91Q40264576-6EC81AD0-032C-4C7C-9B60-36D765B92612Q40405782-958454B2-28ED-40BE-A9EB-872E5978CD53
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniela M Zisterer
@ast
Daniela M Zisterer
@en
Daniela M Zisterer
@es
Daniela M Zisterer
@nl
type
label
Daniela M Zisterer
@ast
Daniela M Zisterer
@en
Daniela M Zisterer
@es
Daniela M Zisterer
@nl
prefLabel
Daniela M Zisterer
@ast
Daniela M Zisterer
@en
Daniela M Zisterer
@es
Daniela M Zisterer
@nl
P106
P21
P31
P496
0000-0001-5005-1023